World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
Video by @JohnPLeonardMD @oncodaily on our STAMP (EA6174) study, the largest clinical trial of immunotherapy as adjuvant treatment for Merkel cell carcinoma after surgery (supported by @theNCI). Hear @JaniceM10 describe the findings presented at #ASCO26. #melanoma #pembrolizumab
STAMP Trial in Adjuvant Treatment of Merkel Cell Carcinoma - John Leonard
@JohnPLeonardMD
https://oncodaily.com/voices/john-leonard-514543
STAMP EA6174 Trial #ASCO26 | Interview w @JaniceM10 @Perlmutter_CC in ASCO Daily News | First evidence that #pembrolizumab may benefit Merkel cell cancer patients at relapse, especially those at high risk of spread to distant organs. #melanoma @LutzkyJose
New STAMP Analysis: Adjuvant Pembro May Reduce Risk of Disease-Related Events in Merkel Cell...
In a new exploratory analysis, the STAMP trial shows that pembrolizumab is associated with improvements over observati...
bit.ly
#LungCancer Trial Results | EA5142 ANVIL ALCHEMIST | @JAMA_current & #ASCO26. Grateful to
@ChaftJamie
@KurtOettelMD
@charlesrudin
@BFallerMD
@LuisRaezMD
@eevokes
@drgandara
@RamalingamMD
+ all the authors for their leadership of this important adjuvant study supported by @theNCI
In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in #tumors with high PD-L1 expression.
#ASCO26 @ASCO
https://ja.ma/4x2vSYy
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
33
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
